Literature DB >> 21415726

The ubiquitin-proteasome system in cardiomyopathies.

Saskia Schlossarek1, Lucie Carrier.   

Abstract

PURPOSE OF REVIEW: Fine equilibrium between protein synthesis and protein degradation is essential for cell survival and function. After initial synthesis, membrane and secretory proteins are modified, folded, and assembled in the endoplasmic reticulum, whereas other proteins are synthesized and processed in the cytosol. Proteins are subject to different quality control systems to minimize aberrant production that could lead to cellular damage. The molecular chaperones help protein folding and stabilization, whereas the ubiquitin-proteasome system (UPS) and lysosomes degrade proteins. The UPS has been increasingly recognized as a major system involved in several biological processes such as cell proliferation, adaptation to stress and cell death. RECENT
FINDINGS: A number of studies have recently outlined the functional significance of the UPS in cardiovascular physiology and disease. Particularly, activation or impairment of the UPS has been reported in cardiac disease such as cardiac hypertrophy, myocardial ischemia and heart failure. Recent evidence indicates that the UPS plays a pathogenic role in hypertrophic cardiomyopathy and desmin-related cardiomyopathy.
SUMMARY: Since the clinical importance of the UPS is rapidly expanding, it has emerged as a potential target for therapy of cardiac disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21415726     DOI: 10.1097/HCO.0b013e32834598fe

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  33 in total

1.  Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.

Authors:  Saskia Schlossarek; Friederike Schuermann; Birgit Geertz; Giulia Mearini; Thomas Eschenhagen; Lucie Carrier
Journal:  J Muscle Res Cell Motil       Date:  2011-11-11       Impact factor: 2.698

Review 2.  Regulation of proteasome activity in health and disease.

Authors:  Marion Schmidt; Daniel Finley
Journal:  Biochim Biophys Acta       Date:  2013-08-27

3.  Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.

Authors:  Constantine S Mitsiades
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

Review 4.  Proteasome dysfunction in cardiomyopathies.

Authors:  Jennifer E Gilda; Aldrin V Gomes
Journal:  J Physiol       Date:  2017-03-16       Impact factor: 5.182

5.  FAT10 protects cardiac myocytes against apoptosis.

Authors:  Xiaogang Peng; Jianghua Shao; Yang Shen; Yunguo Zhou; Qing Cao; Jinzhu Hu; Wenfeng He; Xin Yu; Xiuxia Liu; Ali J Marian; Kui Hong
Journal:  J Mol Cell Cardiol       Date:  2013-02-13       Impact factor: 5.000

6.  Cardiac myosin binding protein-C: redefining its structure and function.

Authors:  Sakthivel Sadayappan; Pieter P de Tombe
Journal:  Biophys Rev       Date:  2012-06-01

7.  Clarifying the cardiac proteasome paradox: protein quality control.

Authors:  Christopher C Glembotski
Journal:  Circ Res       Date:  2012-08-17       Impact factor: 17.367

Review 8.  The ubiquitin proteasome system in human cardiomyopathies and heart failure.

Authors:  Sharlene M Day
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-03-11       Impact factor: 4.733

9.  Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins.

Authors:  Mark J Ranek; Erin J M Terpstra; Jie Li; David A Kass; Xuejun Wang
Journal:  Circulation       Date:  2013-06-14       Impact factor: 29.690

10.  The COP9 signalosome is required for autophagy, proteasome-mediated proteolysis, and cardiomyocyte survival in adult mice.

Authors:  Huabo Su; Jie Li; Hanna Osinska; Faqian Li; Jeffrey Robbins; Jinbao Liu; Ning Wei; Xuejun Wang
Journal:  Circ Heart Fail       Date:  2013-07-19       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.